Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 6/2016

01-06-2016 | Original Article

Staphylococcus aureus and Pseudomonas aeruginosa co-infection is associated with cystic fibrosis-related diabetes and poor clinical outcomes

Authors: D. H. Limoli, J. Yang, M. K. Khansaheb, B. Helfman, L. Peng, A. A. Stecenko, J. B. Goldberg

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 6/2016

Login to get access

Abstract

Cystic fibrosis-related diabetes (CFRD) patients suffer from accelerated rates of pulmonary decline compared to cystic fibrosis (CF) patients with normal glucose tolerance (NGT). However, the mechanisms underlying this difference are unknown. While CFRD is associated with increased respiratory infections, a link between infection and enhanced pulmonary dysfunction remains unclear. The development of glucose intolerance is spectral, resulting in impaired glucose tolerance (IGT) prior to the diagnosis of CFRD. Inclusion of IGT patients within the NGT group may diminish the ability to identify correlations with CFRD. With this in mind, this study aimed to determine if the association between CFRD and respiratory infections is correlated with pulmonary decline. Respiratory cultures from 234 CF patients with confirmed diagnosis of NGT or CFRD were analyzed to measure rates of infection, focusing on the two most prevalent bacteria in CF, Staphylococcus aureus and Pseudomonas aeruginosa. Infection status was correlated with pulmonary function and confounding clinical variables including age, gender, blood glucose levels, and CF transmembrane conductance regulator (CFTR) phenotype were considered in multivariate analyses. CFRD patients, particularly those with extremely high blood glucose levels, were more likely than NGT patients to be co-infected with S. aureus and P. aeruginosa, compared to infection with only one pathogen. Co-infection was associated with decreased lung function and increased frequency of pulmonary exacerbations, even after adjustment for confounding variables. Alterations in the microbial community composition, as opposed to the presence of a single pathogen, may account for greater pulmonary decline in CFRD patients.
Literature
4.
go back to reference Finkelstein SM, Wielinski CL, Elliott GR, Warwick WJ, Barbosa J, Wu SC et al (1988) Diabetes mellitus associated with cystic fibrosis. J Pediatr 112:373–377CrossRefPubMed Finkelstein SM, Wielinski CL, Elliott GR, Warwick WJ, Barbosa J, Wu SC et al (1988) Diabetes mellitus associated with cystic fibrosis. J Pediatr 112:373–377CrossRefPubMed
5.
go back to reference Koch C, Rainisio M, Madessani U, Harms HK, Hodson ME, Mastella G et al (2001) Presence of cystic fibrosis-related diabetes mellitus is tightly linked to poor lung function in patients with cystic fibrosis: data from the European Epidemiologic Registry of Cystic Fibrosis. Pediatr Pulmonol 32:343–350. doi:10.1002/ppul.1142 CrossRefPubMed Koch C, Rainisio M, Madessani U, Harms HK, Hodson ME, Mastella G et al (2001) Presence of cystic fibrosis-related diabetes mellitus is tightly linked to poor lung function in patients with cystic fibrosis: data from the European Epidemiologic Registry of Cystic Fibrosis. Pediatr Pulmonol 32:343–350. doi:10.​1002/​ppul.​1142 CrossRefPubMed
7.
go back to reference Milla CE, Warwick WJ, Moran A (2000) Trends in pulmonary function in patients with cystic fibrosis correlate with the degree of glucose intolerance at baseline. Am J Respir Crit Care Med 162:891–895CrossRefPubMed Milla CE, Warwick WJ, Moran A (2000) Trends in pulmonary function in patients with cystic fibrosis correlate with the degree of glucose intolerance at baseline. Am J Respir Crit Care Med 162:891–895CrossRefPubMed
8.
go back to reference Kerem E, Viviani L, Zolin A, MacNeill S, Hatziagorou E, Ellemunter H et al (2014) Factors associated with FEV1 decline in cystic fibrosis: analysis of the ECFS patient registry. Eur Respir J 43:125–133CrossRefPubMed Kerem E, Viviani L, Zolin A, MacNeill S, Hatziagorou E, Ellemunter H et al (2014) Factors associated with FEV1 decline in cystic fibrosis: analysis of the ECFS patient registry. Eur Respir J 43:125–133CrossRefPubMed
9.
go back to reference Parkins MD, Rendall JC, Elborn JS (2012) Incidence and risk factors for pulmonary exacerbation treatment failures in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa. Chest 141:485–493. doi:10.1378/chest.11-0917 CrossRefPubMed Parkins MD, Rendall JC, Elborn JS (2012) Incidence and risk factors for pulmonary exacerbation treatment failures in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa. Chest 141:485–493. doi:10.​1378/​chest.​11-0917 CrossRefPubMed
10.
go back to reference Lanng S, Thorsteinsson B, Nerup J, Koch C (1994) Diabetes mellitus in cystic fibrosis: effect of insulin therapy on lung function and infections. Acta Paediatr 83:849–853CrossRefPubMed Lanng S, Thorsteinsson B, Nerup J, Koch C (1994) Diabetes mellitus in cystic fibrosis: effect of insulin therapy on lung function and infections. Acta Paediatr 83:849–853CrossRefPubMed
11.
go back to reference Merlo CA, Boyle MP, Diener-West M, Marshall BC, Goss CH, Lechtzin N (2007) Incidence and risk factors for multiple antibiotic-resistant Pseudomonas aeruginosa in cystic fibrosis. Chest 132:562–568. doi:10.1378/chest.06-2888 CrossRefPubMed Merlo CA, Boyle MP, Diener-West M, Marshall BC, Goss CH, Lechtzin N (2007) Incidence and risk factors for multiple antibiotic-resistant Pseudomonas aeruginosa in cystic fibrosis. Chest 132:562–568. doi:10.​1378/​chest.​06-2888 CrossRefPubMed
12.
16.
go back to reference Knudson RJ, Lebowitz MD, Holberg CJ, Burrows B (1983) Changes in the normal maximal expiratory flow-volume curve with growth and aging. Am Rev Respir Dis 127(6):725–734PubMed Knudson RJ, Lebowitz MD, Holberg CJ, Burrows B (1983) Changes in the normal maximal expiratory flow-volume curve with growth and aging. Am Rev Respir Dis 127(6):725–734PubMed
17.
go back to reference Moran A, Brunzell C, Cohen RC, Katz M, Marshall BC, Onady G et al (2010) Clinical care guidelines for cystic fibrosis-related diabetes. Diabetes Care 33:2697–2708CrossRefPubMedPubMedCentral Moran A, Brunzell C, Cohen RC, Katz M, Marshall BC, Onady G et al (2010) Clinical care guidelines for cystic fibrosis-related diabetes. Diabetes Care 33:2697–2708CrossRefPubMedPubMedCentral
18.
go back to reference Hubert D, Réglier-Poupet H, Sermet-Gaudelus I, Ferroni A, Le Bourgeois M, Burgel P-R et al (2013) Association between Staphylococcus aureus alone or combined with Pseudomonas aeruginosa and the clinical condition of patients with cystic fibrosis. J Cyst Fibros 12:497–503. doi:10.1016/j.jcf.2012.12.003 CrossRefPubMed Hubert D, Réglier-Poupet H, Sermet-Gaudelus I, Ferroni A, Le Bourgeois M, Burgel P-R et al (2013) Association between Staphylococcus aureus alone or combined with Pseudomonas aeruginosa and the clinical condition of patients with cystic fibrosis. J Cyst Fibros 12:497–503. doi:10.​1016/​j.​jcf.​2012.​12.​003 CrossRefPubMed
20.
go back to reference Wood DM, Brennan AL, Philips BJ, Baker EH (2004) Effect of hyperglycaemia on glucose concentration of human nasal secretions. Clin Sci (Lond) 106:527–533. doi:10.1042/CS20030333 CrossRef Wood DM, Brennan AL, Philips BJ, Baker EH (2004) Effect of hyperglycaemia on glucose concentration of human nasal secretions. Clin Sci (Lond) 106:527–533. doi:10.​1042/​CS20030333 CrossRef
21.
go back to reference Baker EH, Clark N, Brennan AL, Fisher DA, Gyi KM, Hodson ME et al (2007) Hyperglycemia and cystic fibrosis alter respiratory fluid glucose concentrations estimated by breath condensate analysis. J Appl Physiol (1985) 102:1969–1975. doi:10.1152/japplphysiol.01425.2006 CrossRef Baker EH, Clark N, Brennan AL, Fisher DA, Gyi KM, Hodson ME et al (2007) Hyperglycemia and cystic fibrosis alter respiratory fluid glucose concentrations estimated by breath condensate analysis. J Appl Physiol (1985) 102:1969–1975. doi:10.​1152/​japplphysiol.​01425.​2006 CrossRef
23.
go back to reference Philips BJ, Redman J, Brennan A, Wood D, Holliman R, Baines D et al (2005) Glucose in bronchial aspirates increases the risk of respiratory MRSA in intubated patients. Thorax [Internet] 60:761–764CrossRef Philips BJ, Redman J, Brennan A, Wood D, Holliman R, Baines D et al (2005) Glucose in bronchial aspirates increases the risk of respiratory MRSA in intubated patients. Thorax [Internet] 60:761–764CrossRef
26.
go back to reference Yano H, Kinoshita M, Fujino K, Nakashima M, Yamamoto Y, Miyazaki H et al (2012) Insulin treatment directly restores neutrophil phagocytosis and bactericidal activity in diabetic mice and thereby improves surgical site Staphylococcus aureus infection. Infect Immun 80(12):4409–4416. doi:10.1128/IAI.00787-12 CrossRefPubMedPubMedCentral Yano H, Kinoshita M, Fujino K, Nakashima M, Yamamoto Y, Miyazaki H et al (2012) Insulin treatment directly restores neutrophil phagocytosis and bactericidal activity in diabetic mice and thereby improves surgical site Staphylococcus aureus infection. Infect Immun 80(12):4409–4416. doi:10.​1128/​IAI.​00787-12 CrossRefPubMedPubMedCentral
Metadata
Title
Staphylococcus aureus and Pseudomonas aeruginosa co-infection is associated with cystic fibrosis-related diabetes and poor clinical outcomes
Authors
D. H. Limoli
J. Yang
M. K. Khansaheb
B. Helfman
L. Peng
A. A. Stecenko
J. B. Goldberg
Publication date
01-06-2016
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 6/2016
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-016-2621-0

Other articles of this Issue 6/2016

European Journal of Clinical Microbiology & Infectious Diseases 6/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.